Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over 50 in developed countries. The macula -- the small, specialized region at the center of the retina responsible for sharp, detailed vision -- progressively deteriorates, robbing patients of their ability to read, recognize faces, drive, and perform other tasks that depend on central vision. Peripheral vision is typically preserved, which distinguishes AMD from conditions like glaucoma.
For paraoptometrics, AMD is a critical topic because you perform several of the key screening and monitoring tests: Amsler grid testing, visual acuity measurement, OCT imaging, and fundus photography. Understanding the disease well enough to educate patients about home monitoring, AREDS2 supplements, and when to seek urgent care makes you an essential part of the AMD management team.
The CPO and CPOA exams test your knowledge of AMD types, staging, risk factors, the role of testing, and patient education. This guide covers each of these areas with the clinical detail you need.
Dry vs Wet AMD: Understanding the Two Forms
AMD is divided into two forms based on whether abnormal blood vessel growth is present. This distinction is clinically critical because it determines prognosis, urgency, and treatment approach.
Dry (Non-Exudative) AMD
Accounts for approximately 90% of all AMD cases. The hallmark finding is drusen -- yellowish deposits of waste material that accumulate between the retinal pigment epithelium (RPE) and Bruch's membrane. Small, hard drusen are extremely common with aging and not necessarily concerning. Large, soft drusen (over 125 microns, about the width of a retinal vein at the disc margin) are the clinical marker of AMD.
As dry AMD progresses, the RPE becomes irregular -- showing areas of hyperpigmentation (clumping) and hypopigmentation (atrophy). In the most advanced stage, called geographic atrophy, the RPE and overlying photoreceptors die in well-demarcated patches. Geographic atrophy causes permanent scotomas (blind spots) in the affected areas and slowly expands over years.
Vision loss in dry AMD is typically gradual. There is no cure, but AREDS2 supplements can slow progression in intermediate and advanced stages. Importantly, dry AMD can convert to wet AMD at any time.
Wet (Exudative) AMD
Accounts for only about 10% of AMD cases but causes approximately 90% of severe vision loss from AMD. The defining feature is choroidal neovascularization (CNV) -- abnormal new blood vessels growing from the choroid through Bruch's membrane under or into the retina. These vessels are fragile and leaky, releasing fluid and blood into the retinal layers.
The hallmark symptom is sudden metamorphopsia -- straight lines appear wavy or bent. Patients may also notice a sudden decrease in central vision, a new central dark spot, or difficulty reading. On OCT, subretinal or intraretinal fluid is visible. On fundus examination, subretinal hemorrhage or exudates may be present.
Treatment with anti-VEGF injections (ranibizumab, aflibercept, bevacizumab, faricimab) can stabilize or improve vision in many patients by blocking the growth factor that drives abnormal vessel growth. Early detection and prompt treatment significantly improve outcomes, which is why daily Amsler grid monitoring is so important.
AMD Staging and Progression
| Stage | Findings | Vision Impact | Management |
|---|---|---|---|
| Early AMD | Medium drusen (63-125 microns), no pigment changes | Usually none | Monitor, lifestyle counseling, no AREDS2 indicated |
| Intermediate AMD | Large drusen (>125 microns) and/or pigment changes | Mild to moderate; may notice difficulty in dim light | AREDS2 supplements recommended, regular monitoring |
| Late Dry AMD | Geographic atrophy (RPE and photoreceptor loss) | Significant central vision loss | AREDS2, low-vision rehabilitation, emerging therapies |
| Late Wet AMD | Choroidal neovascularization, fluid, hemorrhage | Rapid, potentially severe central vision loss | Urgent anti-VEGF injections, ongoing monitoring |
Risk Factors
Age Over 50
Age is the strongest overall risk factor. AMD prevalence increases sharply after age 50 and continues to rise with each decade. By age 75, the prevalence of intermediate or advanced AMD is substantial. This is why comprehensive eye exams are increasingly important with age.
Smoking
The strongest modifiable risk factor. Smokers have 2-4 times the risk of AMD compared to non-smokers. Smoking increases oxidative damage to the retina and reduces macular pigment density. The risk remains elevated for years after quitting but does decrease over time. Document smoking status and encourage cessation.
Family History
Genetics play a significant role. First-degree relatives of AMD patients have a substantially higher risk. Several genetic variants have been identified, particularly in complement factor H (CFH) and ARMS2 genes. Family history should be documented during patient intake.
Other Factors
Caucasian race, obesity, cardiovascular disease, and UV exposure are additional risk factors. A diet low in leafy green vegetables (which provide lutein and zeaxanthin for macular pigment) may also contribute. AMD is less common in African Americans, though it does occur.
The Paraoptometric's Role in AMD Testing
Paraoptometrics perform several tests critical for AMD detection and monitoring. Each provides different information, and together they give the doctor a comprehensive picture of disease status and progression.
Amsler Grid
A simple but powerful screening tool: a grid of horizontal and vertical lines with a central fixation dot. The patient covers one eye, fixates on the center, and reports any areas where lines appear wavy (metamorphopsia), broken, missing, or blurred. Any distortion is a red flag for macular pathology, particularly wet AMD conversion. The paraoptometric administers this test in-office and educates patients on daily home monitoring.
Visual Acuity Testing
Central VA is the primary functional measure in AMD. Decreased VA, especially near vision, may indicate macular involvement. A sudden drop in VA in a patient with known dry AMD should raise concern for wet AMD conversion. Document VA carefully at each visit for comparison.
OCT (Optical Coherence Tomography)
OCT is the single most important imaging tool for AMD management. It provides cross-sectional images of the retinal layers, allowing visualization of drusen, RPE changes, geographic atrophy, subretinal and intraretinal fluid, and pigment epithelial detachments. In patients receiving anti-VEGF treatment for wet AMD, OCT is performed at every visit to assess treatment response. The paraoptometric captures the scans and ensures image quality.
Fundus Photography
Color fundus photos document drusen, pigment changes, hemorrhage, and exudates. Widefield imaging captures a larger area of the retina. Serial photographs allow comparison of drusen size and distribution over time, detection of new hemorrhage, and documentation of geographic atrophy expansion. These images become part of the permanent medical record.
Practice AMD questions for your certification exam
Opterio covers dry vs wet AMD, staging, AREDS2 supplements, and testing protocols with AI-powered explanations.
Patient Education: A Critical Paraoptometric Responsibility
AMD patient education can directly impact visual outcomes. Patients who understand their condition, monitor at home, and seek prompt care when changes occur have better prognoses. The paraoptometric often spends more time with the patient than the doctor and is well-positioned to reinforce these messages.
Daily Amsler Grid Monitoring
Teach patients to check the Amsler grid every day, one eye at a time, while wearing their reading glasses. They should fixate on the central dot and note any areas of waviness, distortion, blurriness, or missing sections. Any new changes should prompt an urgent call to the office. Provide a physical grid and demonstrate proper technique before the patient leaves.
AREDS2 Supplements
For patients with intermediate or advanced AMD, the doctor may recommend AREDS2 supplements. Help patients understand these are a specific formulation (vitamins C, E, zinc, copper, lutein, zeaxanthin) that has been shown to reduce progression risk by about 25% -- not a general multivitamin. Patients should look for products labeled "AREDS2 formula" and take them as directed. These supplements do not reverse existing damage but help protect remaining vision.
When to Seek Urgent Care
Patients must understand that any sudden change in vision -- new distortion, sudden blur, or new dark spot -- could indicate wet AMD conversion and requires urgent evaluation. This is not something that can wait for the next scheduled appointment. Early treatment of wet AMD with anti-VEGF injections can prevent significant vision loss, but delays reduce treatment effectiveness.
Lifestyle Modifications
Smoking cessation is the single most impactful lifestyle change for AMD risk reduction. A diet rich in dark leafy greens (kale, spinach, collard greens) provides lutein and zeaxanthin, which form the protective macular pigment. Regular cardiovascular exercise, maintaining a healthy weight, and wearing UV-protective sunglasses are also beneficial.
Dry-to-Wet AMD Conversion: Recognize the Signs
A patient with known dry AMD who reports new metamorphopsia (wavy or distorted vision), a sudden decrease in visual acuity, or a new central dark spot may be converting to wet AMD. This requires urgent evaluation -- ideally same-day OCT to look for subretinal or intraretinal fluid. If wet AMD is confirmed, anti-VEGF treatment should begin as soon as possible. Delays of even weeks can result in permanent vision loss.